Warren Buffett says "Be fearful when others are greedy."
Our A.I. playbook shows you exactly when that moment arrives and how to position for maximum protection and profit potential.
This A.I. system just flagged five specific stocks showing pattern formations that suggest major trend reversals are imminent. These crystal-clear signals rarely align like this.
August's market conditions laid the groundwork for these perfect opportunities, and our A.I. is detecting momentum shifts – IN BOTH DIRECTIONS - that most traders are missing.
Join our LIVE A.I. Stock Watchlist session to see all 5 stocks and learn what the data reveals about their potential moves.
Bring 2-3 ticker symbols you're trading - we'll analyze as many as we can.
Lane Mendelsohn, President
Vantagepoint AI, LLC
1-800-732-5407 U.S. & Canada
1-813-973-0496 International
3 Under-the-Radar Biotechs Under $5 That Could Soar 200%
Written by Chris Markoch. Published 9/9/2025.
Key Points
- Hoth Therapeutics is advancing mRNA-based therapies for cancer and obesity, with analyst targets implying over 150% upside.
- Silo Pharma combines pre-clinical psychedelic therapies with an obesity drug collaboration and a unique crypto treasury strategy.
- Anixa Biosciences develops cancer immunotherapies in partnership with leading institutions, with nearly 200% analyst upside potential.
Biotechnology stocks often appeal to speculative investors because many companies are still in clinical or preclinical stages. They are not yet profitable—and some are even pre-revenue—so any potential payoff may be years away. Additionally, a large number of these names trade below $5 per share, attracting traders looking for penny-stock momentum.
Yet for patient, conviction-driven investors, small-cap biotech stocks can offer a chance to build positions with the potential for outsized long-term returns. Here are three under-the-radar biotech names trading under $5 that might reward long-term holders.
Hoth: Preclinical Cancer Research with Large Market Upside
Musk's Project Colossus could mint millionaires (Ad)
I predict this single breakthrough could make Elon the world's first trillionaire — and mint more new millionaires than any tech advance in history.
And for a limited time, you have the chance to claim a stake in this project, even though it's housed inside Elon's private company, xAI.
Hoth Therapeutics Inc. (NASDAQ: HOTH) is the top performer on this list, with shares up 98% in 2025. Even so, at roughly $1.50, HOTH sits 35% below its 12-month high from January.
Hoth's pipeline includes six candidates—two in active clinical trials and four in preclinical development—spanning oncology and obesity. Its lead oncology program, HT-KIT, leverages mRNA technology to target gastrointestinal stromal tumors (GIST), systemic mastocytosis and certain leukemias. In vitro data show HT-KIT achieves more than 80% knockdown of KIT expression, the key oncogenic driver in these cancers.
The company's preclinical obesity candidate, HT-VA, is licensed exclusively from the U.S. Department of Veterans Affairs and aims at a market projected to exceed $100 billion globally. Analysts see further upside for HOTH, with a consensus price target of $4, implying roughly 150% potential gain from current levels.
Silo Pharma: Psychedelics, Obesity and a Crypto Treasury Strategy
Silo Pharma Inc. (NASDAQ: SILO) has slid 29% year-to-date but is up more than 7% over the past three months. That recent strength largely comes from a nonbinding letter of intent to form a 50/50 joint venture with Hoth Therapeutics to develop the HT-VA obesity candidate.
Beyond obesity, Silo focuses on novel formulations of traditional and psychedelic therapeutics. Its pipeline contains four preclinical programs, including SP-26 for fibromyalgia and SPU-16 for multiple sclerosis (details here).
In a unique strategic move, Silo has also launched a cryptocurrency treasury strategy, allocating capital to Bitcoin, Ethereum and Solana. The company plans to stake assets to generate yield while prioritizing capital preservation.
Anixa: Micro-Cap Cancer Play with Major Partnerships
Anixa Biosciences (NASDAQ: ANIX) targets oncology with a pipeline of five candidates, two of which are in Phase 1 trials. One program uses CAR-T immunotherapy to treat ovarian cancer by arming patients' T cells to attack tumor cells. The other employs vaccine technology to generate tumor-specific antigens (full pipeline).
Anixa's programs benefit from partnerships with the Moffitt Cancer Center, the Cleveland Clinic and the U.S. Department of Defense. Coverage is limited, but three analysts collectively assign ANIX a consensus price target of $10, suggesting nearly 200% upside from current levels.
This email communication is a paid advertisement from Vantage Point, a third-party advertiser of DividendStocks.com and MarketBeat.
Note: The above chart is from past data and may be atypical trading involves risk and may not be suitable for all investors. Past results do not guarantee future performance.
If you need help with your account, please don't hesitate to email our U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. USA..